维生素D与ω-3脂肪酸试验(VITAL)骨骼健康辅助研究:女性和男性中与小梁骨评分相关的临床因素
该研究为VITAL试验骨骼健康辅助研究的基线横断面分析,纳入672名参与者(369名男性、303名女性),平均年龄63.5±6.0岁。结果显示较低的小梁骨评分(TBS)与女性、年龄增长、BMI≥25 kg/m2、使用SSRI、高酒精摄入及糖尿病相关,脆性骨折史与较低TBS呈趋势性关联。
要点
- 男性TBS高于女性(1.311 vs 1.278,P<0.001)。
- BMI升高、年龄增长、糖尿病、使用SSRI及高酒精摄入与较低TBS相关。
- 脆性骨折史与较低TBS呈趋势性关联(P=0.072)。
核心结论
- 较低TBS与女性、年龄增长、BMI≥25 kg/m2、使用SSRI、酒精摄入及糖尿病相关;脆性骨折史与较低TBS之间呈趋势性关联。
- TBS可能有助于临床评估超重或肥胖、使用SSRI或糖尿病患者中可能与骨折相关的结构变化。
- 正在进行的随访研究将阐明补充维生素D3和/或脂肪酸对TBS及其他骨骼健康指标的影响。
研究设计与样本
- VITAL试验骨骼健康辅助研究的基线横断面分析,纳入672名参与者(369名男性、303名女性),平均年龄63.5±6.0岁。
- 纳入条件包括BMI≤37 kg/m2,且2年内未使用双膦酸盐或1年内未使用其他骨活性药物。
主要发现
- 男性TBS高于女性(1.311 vs 1.278,P<0.001)。
- BMI升高(P<0.001)、年龄增长(P=0.004)、糖尿病(P=0.008)、使用SSRI(P=0.044)及高酒精摄入(P=0.009)与较低TBS相关。
- 脆性骨折史与较低TBS呈趋势性关联(P=0.072)。
- 按种族、吸烟、跌倒史及复合维生素或咖啡因使用分析时,TBS未见差异。
临床怎么用
- 作者认为TBS可能有助于临床评估超重或肥胖、使用SSRI或糖尿病患者中可能与骨折相关的结构变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We investigated the association of clinical variables with TBS at baseline in the bone health sub-cohort of the VITamin D and OmegA-3 TriaL (VITAL). Lower TBS was associated with female sex, aging, BMI ≥ 25 kg/m2, SSRI use, high alcohol intake, and presence of diabetes; there was a trend towards significance between lower TBS and history of fragility fractures. INTRODUCTION: We investigated whether TBS differs by sex, race, body mass index (BMI), and other clinical variables. METHODS: The VITamin D and OmegA-3 TriaL (VITAL) is determining effects of vitamin D3 and/or omega-3 fatty acid (FA) supplements in reducing risks of cancer and cardiovascular disease. In the VITAL: Effects on Bone Structure/Architecture ancillary study, effects of these interventions on bone will be investigated. Here, we examine the associations of clinical risk factors with TBS assessments at baseline in the bone health sub-cohort, comprised of 672 participants (369 men and 303 women), mean (± SD) age 63.5 ± 6.0 years; BMI ≤ 37 kg/m2, no bisphosphonates within 2 years or other bone active medications within 1 year. RESULTS: TBS was greater in men than women (1.311 vs. 1.278, P < 0.001) and lower with elevated BMIs (P < 0.001), higher age (P = 0.004), diabetes (P = 0.008), SSRI use (P = 0.044), and high alcohol intake (P = 0.009). There was a trend for history of fragility fractures (P = 0.072), and lower TBS. TBS did not vary when analyzed by race, smoking, history of falls, and multivitamin or caffeine use. CONCLUSIONS: Lower TBS was associated with female sex, aging, BMI ≥ 25 kg/m2, SSRI use, alcohol use, and presence of diabetes; there was a trend between lower TBS and history of fragility fractures. TBS may be useful clinically to assess structural changes that may be associated with fractures among patients who are overweight or obese, those on SSRIs, or with diabetes. Ongoing follow-up studies will clarify the effects of supplemental vitamin D3 and/or FA's on TBS and other bone health measures. TRIAL REGISTRATION: NCT01747447.
引用
- Goldman AL, Donlon CM, Cook NR, et al. VITamin D and OmegA-3 TriaL (VITAL) bone health ancillary study: clinical factors associated with trabecular bone score in women and men. Osteoporos Int. 2018. PMID: 30022253. doi:10.1007/s00198-018-4633-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。